Eiger Obtains License To Hepatitis C Virus Technology From Stanford

Eiger has acquired exclusive worldwide license to novel Hepatitis C Virus (HCV) technology from the Stanford University.

The technology is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication.

David Cory, president and CEO of Eiger, said: “We are delighted to have licensed the rights to this exciting new technology from Stanford University. Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients.